Program Guide – ASCO Meeting Program Guide

Dae Kim H. Lee Moffitt Cancer Center and Research Institute Dae Kim , Lauren Ponto , Allan Pereira , Richard Kim , Chandler Kracht , Gregory Lauwers , Jose Pimiento , Tiago Biachi de Castria , Jonathan Strosberg , Mintallah Haider , Iman Imanirad , Trenton Avriett , James Costello , Sarah Hoffe , Dung-Tsa Chen , Sarbajit Mukherjee , Rutika Mehta H. Lee Moffitt Cancer Center and Research Institute, H. Lee Moffitt Cancer Center, Department of Gastrointestinal Oncology, H. Lee Moffitt Cancer Center &

Read the full article here

Source: meetings.asco.org

Categories: Oncologists1, General Medicine News

Tags: GI25

Tweets with this article

MoffittCancerCenter

Join Dae Won Kim, MD today at ASCO GI for a discussion on a phase II study of neratinib (Nera) in combination with chemotherapy/trastuzumab/pembrolizumab (C/T/P) in HER2 overexpressing gastroesophageal cancers. #GI25 Read more: https://t.co/FXcCcBn56r @ASCO https://t.co/DVEiHpJqqB

Program Guide – ASCO Meeting Program Guide

Jonathan Strosberg H. Lee Moffitt Cancer Center and Research Institute Jonathan Strosberg , Anna Koumarianou , Rachel Riechelmann , Jorge Hernando , Sara Cingarlini ,…

MoffittCancerCenter January 23, 2025

Nivolumab Plus Chemo Shows Long-Term OS Benefit in Chinese Patients With Advanced Gastric, GEJ, or Esophageal Cancer

Nivolumab plus chemotherapy demonstrated long-term survival benefits in advanced gastric, GEJ, or esophageal cancer in China.

OncLive.com January 23, 2025

Laura, Marginal Zone Lymphoma

Laura, Marginal Zone Lymphoma In late 2018, I was 60 years old and had been losing weight and working on getting into better shape. At…

LymphomaResearch January 23, 2025

A Phase 1 Clinical Trial of NKTR-255 With CD19-22 CAR T-Cell Therapy for Refractory B-Cell Acute Lymphoblastic Leukemia

Researchers at Stanford University have conducted a phase 1 clinical trial (#NCT03233854) evaluating the combination of a bispecific chimeric antigen receptor (CAR) T-cell therapy targeting…

ASTCT January 23, 2025

Overview of the DESTINY-Breast12 Study

Panelists discuss the findings from the DESTINY-Breast12 study, focusing on the efficacy and safety of trastuzumab deruxtecan in patients with HER2-low breast cancer and its…

Targeted Oncology January 23, 2025

Cancer Incidence Continues to Rise, Especially in Women Younger Than 65

Of note, lung cancer incidence was higher among women younger than 65 compared with their male counterparts in 2021.

Cancer Network January 23, 2025

Glucarpidase improves recovery after chemotherapy-induced kidney toxicity

Glucarpidase significantly improved kidney function for patients who developed acute kidney injury from high-dose methotrexate, according to results of a large, multicenter observational study.Glucarpidase (Voraxaze,…

HemOnc Today January 23, 2025

First-Line Tislelizumab Plus Chemo Elicits Deep Responses Linked to OS Benefits in ESCC

OS benefits with tislelizumab plus chemotherapy were comparable between early and late responders in the phase 3 RATIONALE-306 study in patients with ESCC.

OncLive.com January 23, 2025

JNCCN 360 – Advanced Skin Cancers – Mehran Yusuf, MD, on Treating Merkel Cell Carcinoma: A Radiation Oncology Perspective

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of…

Journal of the @NCCN January 23, 2025

Honoring Excellence: Q and A with Dr. Cassandra Fritz of the Washington University in St. Louis Internal Medicine Residency Program

A Q and A with Dr. Cassandra Fritz from the WashU internal medicine program. The program is receiving a 2025 ACGME Barbara Ross-Lee, DO DEI…

Washington U. Med January 23, 2025

Related Articles